{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T10:01:56Z","timestamp":1789984916887,"version":"4.0.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,8,20]],"date-time":"2018-08-20T00:00:00Z","timestamp":1534723200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s12032-018-1195-3","type":"journal-article","created":{"date-parts":[[2018,8,20]],"date-time":"2018-08-20T03:31:07Z","timestamp":1534735867000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Significance of introduction of alternative dosing schedule for sunitinib during first-line treatment of patients with metastatic renal cell carcinoma"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0563-4160","authenticated-orcid":false,"given":"Hideaki","family":"Miyake","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuto","family":"Matsushita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromitsu","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahisa","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Motoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Otsukav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,20]]},"reference":[{"key":"1195_CR1","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1517\/13543780902980171","volume":"18","author":"HK Gan","year":"2009","unstructured":"Gan HK, Seruga B, Knox JJ. Sunitinib in solid tumors. Expert Opin Investig Drugs. 2009;18:821\u201334.","journal-title":"Expert Opin Investig Drugs"},{"key":"1195_CR2","first-page":"327","volume":"9","author":"DB Mendel","year":"2003","unstructured":"Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship. Clin Cancer Res. 2003;9:327\u201337.","journal-title":"Clin Cancer Res"},{"key":"1195_CR3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"RJ Motzer","year":"2007","unstructured":"Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115\u201324.","journal-title":"N Engl J Med"},{"key":"1195_CR4","doi-asserted-by":"publisher","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","volume":"27","author":"RJ Motzer","year":"2009","unstructured":"Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:3584\u201390.","journal-title":"J Clin Oncol"},{"key":"1195_CR5","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/bjc.2015.196","volume":"113","author":"ME Gore","year":"2015","unstructured":"Gore ME, Szczylik C, Porta C, et al. Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma. Br J Cancer. 2015;113:12\u20139.","journal-title":"Br J Cancer"},{"key":"1195_CR6","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1007\/s12032-014-0978-4","volume":"31","author":"H Miyake","year":"2014","unstructured":"Miyake H, Miyazaki A, Harada K, Fujisawa M. Assessment of efficacy, safety and quality of life of 110 patients treated with sunitinib as first-line therapy for metastatic renal cell carcinoma: experience in real-world clinical practice in Japan. Med Oncol. 2014;31:978.","journal-title":"Med Oncol"},{"key":"1195_CR7","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.critrevonc.2016.08.012","volume":"107","author":"B Rousseau","year":"2016","unstructured":"Rousseau B, Kempf E, Desamericq G, et al. First-line antiangiogenics for metastatic renal cell carcinoma: a systematic review and network meta-analysis. Crit Rev Oncol Hematol. 2016;107:44\u201353.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1195_CR8","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1200\/JCO.2005.02.2194","volume":"24","author":"S Faivre","year":"2006","unstructured":"Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol. 2006;24:25\u201335.","journal-title":"J Clin Oncol"},{"key":"1195_CR9","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1517\/14656566.2012.689130","volume":"13","author":"L Wood","year":"2012","unstructured":"Wood L. Sunitinib malate for the treatment of renal cell carcinoma. Expert Opin Pharmacother. 2012;13:1323\u201336.","journal-title":"Expert Opin Pharmacother"},{"key":"1195_CR10","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s00280-009-1170-y","volume":"66","author":"BE Houk","year":"2010","unstructured":"Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic\/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol. 2010;66:357\u201371.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1195_CR11","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1080\/14737140.2017.1276830","volume":"17","author":"S Bracarda","year":"2017","unstructured":"Bracarda S, Negrier S, Casper J, et al. How clinical practice is changing the rules: the sunitinib 2\/1 schedule in metastatic renal cell carcinoma. Expert Rev Anticancer Ther. 2017;17:227\u201333.","journal-title":"Expert Rev Anticancer Ther"},{"key":"1195_CR12","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.juro.2013.08.090","volume":"191","author":"BJ Atkinson","year":"2014","unstructured":"Atkinson BJ, Kalra S, Wang X, et al. Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules. J Urol. 2014;191:611\u20138.","journal-title":"J Urol"},{"key":"1195_CR13","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1093\/annonc\/mdv357","volume":"26","author":"JL Lee","year":"2015","unstructured":"Lee JL, Kim MK, Park I, et al. RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial. Ann Oncol. 2015;26:2300\u20135.","journal-title":"Ann Oncol"},{"key":"1195_CR14","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.ejca.2014.01.025","volume":"50","author":"YG Najjar","year":"2014","unstructured":"Najjar YG, Mittal K, Elson P, et al. A 2\u00a0weeks on and 1\u00a0week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma. Eur J Cancer. 2014;50:1084\u20139.","journal-title":"Eur J Cancer"},{"key":"1195_CR15","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s12032-015-0528-8","volume":"32","author":"H Miyake","year":"2015","unstructured":"Miyake H, Harada K, Miyazaki A, Fujisawa M. Improved health-related quality of life of patients with metastatic renal cell carcinoma treated with a 2\u00a0weeks on and 1\u00a0week off schedule of sunitinib. Med Oncol. 2015;32:78.","journal-title":"Med Oncol"},{"key":"1195_CR16","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1093\/annonc\/mdv315","volume":"26","author":"S Bracarda","year":"2015","unstructured":"Bracarda S, Iacovelli R, Boni L, et al. Sunitinib administered on 2\/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis. Ann Oncol. 2015;26:2107\u201313.","journal-title":"Ann Oncol"},{"key":"1195_CR17","doi-asserted-by":"publisher","first-page":"e455","DOI":"10.1016\/j.clgc.2016.10.010","volume":"15","author":"M Ezz El Din","year":"2017","unstructured":"Ezz El Din M. Sunitinib 4\/2 Versus 2\/1 schedule for patients with metastatic renal cell carcinoma: tertiary care hospital experience. Clin Genitourin Cancer. 2017;15:e455\u201362.","journal-title":"Clin Genitourin Cancer"},{"key":"1195_CR18","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1200\/JCO.2002.20.1.289","volume":"20","author":"RJ Motzer","year":"2002","unstructured":"Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002;20:289\u201396.","journal-title":"J Clin Oncol"},{"key":"1195_CR19","doi-asserted-by":"publisher","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","volume":"27","author":"DY Heng","year":"2009","unstructured":"Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27:5794\u20139.","journal-title":"J Clin Oncol"},{"key":"1195_CR20","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3389\/fphar.2017.00523","volume":"8","author":"A Paolo Di","year":"2017","unstructured":"Di Paolo A, Bracarda S, Arrigoni E, et al. Sunitinib in metastatic renal cell carcinoma: the pharmacological basis of the alternative 2\/1 schedule. Front Pharmacol. 2017;8:523.","journal-title":"Front Pharmacol"},{"key":"1195_CR21","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1093\/jjco\/hyp146","volume":"40","author":"H Uemura","year":"2010","unstructured":"Uemura H, Shinohara N, Yuasa T, et al. A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety. Jpn J Clin Oncol. 2010;40:194\u2013202.","journal-title":"Jpn J Clin Oncol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-018-1195-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-018-1195-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-018-1195-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T19:31:45Z","timestamp":1566243105000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-018-1195-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,20]]},"references-count":21,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["1195"],"URL":"https:\/\/doi.org\/10.1007\/s12032-018-1195-3","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,20]]},"assertion":[{"value":"28 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"H. Miyake has received lecture fees from Pfizer. Y. Matsushita, H. Watanabe, K. Tamura, T. Suzuki, D. Motoyama, T. Ito, T. Sugiyama, and A. Otsuka declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants"}},{"value":"Informed consent was waived for individual participants included in the study given the retrospective nature of this work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"133"}}